The Diabetes Screening ecosystem comprises distinct upstream, midstream, and downstream layers that collectively enable the delivery of diagnostic services. Upstream, raw material and component suppliers provide reagents, test strips, and sensor technologies required for assay development. Midstream actors include manufacturers of screening devices, software platforms that integrate biometric data, and system integrators that assemble turnkey solutions for clinics and point‑of‑care sites. Downstream, distributors, health‑system procurement teams, and retail pharmacy networks channel finished products to primary care physicians, community health centers, and occupational health programs, where end users—patients and clinicians—generate clinical value. Value is captured through device sales, consumable replenishment, data‑analytics subscriptions, and reimbursement mechanisms linked to early detection pathways. These interactions generate recurring revenue streams for manufacturers while supporting public‑health objectives through early disease identification.